Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): A double-blind, randomised, placebo-controlled, phase 2 trial

The Lancet Neurology

Volumn 15, Issue 8, 2016, Pages 801-810

  de la Torre, Rafael ^a,c   de Sola, Susana ^a,c   Hernandez, Gimena ^a,c   Farré, Magí ^a,b,c   Pujol, Jesus ^c   Rodriguez, Joan ^a,c   Espadaler, Josep María ^c   Langohr, Klaus ^d,l   Cuenca Royo, Aida ^a,c   Principe, Alessandro ^c   Xicota, Laura ^a,c   Janel, Nathalie ^e   Catuara Solarz, Silvina ^a,m   Sanchez Benavides, Gonzalo ^a   Bléhaut, Henri ^g   del Hoyo, Laura ^a,c   Benejam, Bessy ^h,i   Blanco Hinojo, Laura ^c   Videla, Sebastiá ^a,h,k   Fitó, Montserrat ^a,c   Delabar, Jean Maurice ^e,f   Dierssen, Mara ^a,m   Civit, Ester ^c   Sanchez, Gonzalo ^c   Dueñas Espín, Ivan ^c   Roca, Laia ^c   Legout, Valérie ^g   Sánchez Gutiérrez, Judit ^j   Trias, Katy ^k   Freixas, Rut ^m   more..

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g Institute Jérôme Lejeune   (France)

^h Fundacio Catalana Sindrome de Down   (Spain)

ⁱ Down Syndrome Catalan Foundation   (Spain)

^j Feskits   (Spain)

^k FCSD   (Spain)

^l Service of Psychology   (Spain)

^m CENTRE FOR GENOMIC REGULATION CRG   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; PLACEBO; CATECHIN; CHOLESTEROL; HOMOCYSTEINE; NEUROPROTECTIVE AGENT;

ABDOMINAL PAIN; ADAPTIVE BEHAVIOR; ADAPTIVE BEHAVIOR ASSESSMENT SYSTEM II; ADOLESCENT; ADULT; ARTICLE; ASTHENIA; BEHAVIOR ASSESSMENT; CELIAC DISEASE; COGNITION; COGNITIVE THERAPY; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL INFECTION; GENETIC VARIATION; HEADACHE; HUMAN; INTELLECTUAL IMPAIRMENT; INTELLIGENCE QUOTIENT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MENTAL DISEASE; MOOD DISORDER; MOSAICISM; OUTPATIENT; PARTIAL TRISOMY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SEX; SKIN INFECTION; THERAPY EFFECT; TREMOR; TRISOMY 21; UPPER RESPIRATORY TRACT INFECTION; VISUAL MEMORY; YOUNG ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; COPING BEHAVIOR; DRUG EFFECTS; INHIBITION (PSYCHOLOGY); METABOLISM; RECOGNITION; RETROSPECTIVE STUDY; SPAIN; TREATMENT OUTCOME;

ADAPTATION, PSYCHOLOGICAL; ADULT; CATECHIN; CHOLESTEROL; COGNITION DISORDERS; COGNITIVE THERAPY; DOUBLE-BLIND METHOD; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; INHIBITION (PSYCHOLOGY); MALE; NEUROPROTECTIVE AGENTS; RECOGNITION (PSYCHOLOGY); RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84973365078     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30034-5     Document Type: Article

References (30)

1. de la Torre R, Dierssen M Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. Prog Brain Res 2012, 197:1-14.
2. Dierssen M Down syndrome: the brain in trisomic mode. Nat Rev Neurosci 2012, 13:844-858.
3. Couzens D, Haynes M, Cuskelly M Individual and environmental characteristics associated with cognitive development in Down syndrome: a longitudinal study. J Appl Res Intellect Disabil 2012, 25:396-413.
4. Connolly BH, Morgan SB, Russell FF, Fulliton WL A longitudinal study of children with Down syndrome who experienced early intervention programming. Phys Ther 1993, 73:170-179.
5. Rendeiro C, Rhodes JS, Spencer JP The mechanisms of action of flavonoids in the brain: direct versus indirect effects. Neurochem Int 2015, 89:126-139.
6. Bain J, McLauchlan H, Elliott M, Cohen P The specificities of protein kinase inhibitors: an update. Biochem J 2003, 371:199-204.
7. Lin LC, Wang MN, Tseng TY, Sung JS, Tsai TH Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J Agric Food Chem 2007, 55:1517-1524.
8. Guedj F, Sebrie C, Rivals I, et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 2009, 4:e4606.
9. de la Torre R, De Sola S, Pons M, et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr Food Res 2014, 58:278-288.
10. Pons-Espinal M, Martinez de LM, Dierssen M Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. Neurobiol Dis 2013, 60:18-31.
11. De Sola S, de la Torre R, Sanchez-Benavides G, et al. A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. Front Psychol 2015, 6:708.
12. Pujol J, del Hoyo L, Blanco-Hinojo L, et al. Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. Cortex 2015, 64:148-156.
13. Buffalo EA, Bellgowan PS, Martin A Distinct roles for medial temporal lobe structures in memory for objects and their locations. Learn Mem 2006, 13:638-643.
14. Costanzo F, Varuzza C, Menghini D, et al. Executive functions in intellectual disabilities: a comparison between Williams syndrome and Down syndrome. Res Dev Disabil 2013, 34:1770-1780.
15. Hanna-Pladdy B Dysexecutive syndromes in neurologic disease. J Neurol Phys Ther 2007, 31:119-127.
16. Nardone R, Marth R, Ausserer H, Bratti A, Tezzon F Reduced short latency afferent inhibition in patients with Down syndrome and Alzheimer-type dementia. Clin Neurophysiol 2006, 117:2204-2210.
17. Oberman L, Ifert-Miller F, Najib U, et al. Transcranial magnetic stimulation provides means to assess cortical plasticity and excitability in humans with fragile X syndrome and autism spectrum disorder. Front Synaptic Neurosci 2010, 2:26.
18. Olazaran J, Prieto J, Cruz I, Esteban A Cortical excitability in very mild Alzheimer's disease: a long-term follow-up study. J Neurol 2010, 257:2078-2085.
19. Thomazeau A, Lassalle O, Iafrati J, et al. Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a. J Neurosci 2014, 34:1138-1147.
20. Noll C, Planque C, Ripoll C, et al. DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase. PLoS One 2009, 4:e7540.
21. Noll C, Tlili A, Ripoll C, et al. Dyrk1a activates antioxidant NQO1 expression through an ERK1/2-Nrf2 dependent mechanism. Mol Genet Metab 2012, 105:484-488.
22. Ramakrishna N, Meeker HC, Brown WT Novel epigenetic regulation of alpha-synuclein expression in Down syndrome. Mol Neurobiol 2016, 53:155-162.
23. Vacca RA, Valenti D Green tea EGCG plus fish oil omega-3 dietary supplements rescue mitochondrial dysfunctions and are safe in a Down's syndrome child. Clin Nutr 2015, 34:783-784.
24. Lee SJ, Jia Y The effect of bioactive compounds in tea on lipid metabolism and obesity through regulation of peroxisome proliferator-activated receptors. Curr Opin Lipidol 2015, 26:3-9.
25. Kelemen K, Kiesecker C, Zitron E, et al. Green tea flavonoid epigallocatechin-3-gallate (EGCG) inhibits cardiac hERG potassium channels. Biochem Biophys Res Commun 2007, 364:429-435.
26. Kapetanovic IM, Crowell JA, Krishnaraj R, et al. Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology 2009, 260:28-36.
27. Feng WY Metabolism of green tea catechins: an overview. Curr Drug Metab 2006, 7:755-809.
28. Lovera J, Ramos A, Devier D, et al. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: phase I single group and phase II randomized placebo-controlled studies. J Neurol Sci 2015, 358:46-52.
29. Boada R, Hutaff-Lee C, Schrader A, et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2012, 2:e141.
30. Pujol J, Macia D, Blanco-Hinojo L, et al. Does motion-related brain functional connectivity reflect both artifacts and genuine neural activity?. Neuroimage 2014, 101:87-95.